Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
A user is seeking topical versions of minoxidil and finasteride in Australia that do not contain propylene glycol. They are looking for alternatives due to potential irritation from propylene glycol.
Finasteride's potential side effects, especially sexual dysfunction, are discussed, with emphasis on hormonal balance between testosterone and estradiol. Users share experiences with finasteride, minoxidil, and dutasteride, highlighting the variability in side effects and the influence of mindset and lifestyle.
Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.
A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
The conversation discusses a last-resort hair loss treatment combining topical finasteride, minoxidil, melatonin, and progesterone, with claims that topical finasteride can inhibit up to 52% of scalp DHT. One reply clarifies that progesterone is not an anti-androgen but has anti-androgenic properties because it competes with androgens for receptors.
Finasteride increased testosterone and estrogen, stopped hair loss, and promoted regrowth. Users discussed side effects like libido changes and considered adding minoxidil and aromatase inhibitors.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
The conversation discusses using RU58841 at a 2% concentration as an alternative due to side effects from finasteride. The user plans to start with a lower concentration and increase if necessary.
The conversation discusses using Latanoprost for hair regrowth, with the original poster seeking advice on where to purchase it without a prescription. Users suggest alternatives like Triple Hair's TH-07, which includes Finasteride, Minoxidil, and Latanoprost, and Strut's Latanoprost with melatonin and caffeine.
Finasteride and its effects on hair loss, with discussions on the role of estradiol and estrogen. Users debate whether increased estrogen from DHT blockers contributes to hair regrowth, with concerns about potential side effects like chemical castration.
Minoxidil is commonly used for male pattern baldness, but Procapil is considered to have fewer side effects and be more effective. The user seeks information or experiences regarding Procapil.
The conversation discusses the potential benefits of castor oil for hair thickening, with one user noting it may increase prostaglandin E2 and decrease PGD2. The original poster plans to take 1-2ml orally daily.
Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.